secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-077416
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share
-----------------------------------------------------------------------------

- Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.
- Net proceeds estimated at $141.1M, or $162.3M if over-allotment fully exercised.
- Underwriters include Goldman Sachs, Leerink Partners, Evercore, Barclays; closing expected Feb 27, 2026.
- Proceeds for general corporate purposes; shares sold under existing S-3ASR shelf registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/0001193125-26-077416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/d85338d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-077416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer